United Arab Emirates Ministry of Health and Prevention Approves Biomerica鈥檚 Fortel庐 Ulcer Test for Home Use
Biomerica (Nasdaq: BMRA) has received approval from the UAE Ministry of Health and Prevention for its Fortel庐 Ulcer Test for home use. This 10-minute diagnostic test detects antibodies to Helicobacter pylori (H. pylori), a bacterium affecting 41% of the UAE population and linked to approximately 80% of gastric cancer cases.
The test will be distributed through UAE-based partners and made available at pharmacies, clinics, and online platforms. H. pylori, classified as a Class 1 carcinogen by WHO, can lead to serious complications in up to 20% of infected individuals if untreated, including peptic ulcers and gastric cancer. This approval strengthens Biomerica's presence in the Middle East market, following their successful launch of the EZ Detect鈩� Colon Disease Test.
Biomerica (Nasdaq: BMRA) ha ottenuto l'approvazione dal Ministero della Salute e della Prevenzione degli Emirati Arabi Uniti per il suo Fortel庐 Ulcer Test per uso domiciliare. Questo test diagnostico di 10 minuti rileva gli anticorpi contro Helicobacter pylori (H. pylori), un batterio che interessa il 41% della popolazione degli EAU e collegato a circa il 80% dei casi di cancro gastrico.
Il test sar脿 distribuito tramite partner con sede negli EAU e sar脿 disponibile in farmacie, ambulatori e piattaforme online. L'H. pylori, classificato dall'OMS come carcinogeno di Classe 1, pu貌 causare complicanze gravi nel 20% degli individui infetti se non trattato, incluse ulcere peptiche e cancro gastrico. Questa approvazione rafforza la presenza di Biomerica nel mercato del Medio Oriente, dopo il lancio di successo del test EZ Detect鈩� Colon Disease Test.
Biomerica (Nasdaq: BMRA) ha recibido la aprobaci贸n del Ministerio de Salud y Prevenci贸n de los EAU para su Fortel庐 Ulcer Test de uso dom茅stico. Esta prueba diagn贸stica de 10 minutos detecta anticuerpos contra Helicobacter pylori (H. pylori), una bacteria que afecta al 41% de la poblaci贸n de los EAU y se relaciona con aproximadamente el 80% de los casos de c谩ncer g谩strico.
La prueba se distribuir谩 a trav茅s de socios con base en los EAU y estar谩 disponible en farmacias, cl铆nicas y plataformas online. H. pylori, clasificada por la OMS como carcin贸geno de Clase 1, puede provocar complicaciones graves en hasta el 20% de las personas infectadas si no se trata, incluidas 煤lceras p茅pticas y c谩ncer g谩strico. Esta aprobaci贸n refuerza la presencia de Biomerica en el mercado de Oriente Medio, tras el exitoso lanzamiento del test EZ Detect鈩� Colon Disease Test.
Biomerica (Nasdaq: BMRA)電� 鞛愳偓鞚� 臧�鞝曥毄 Fortel庐 Ulcer Test鞐� 雽�頃� 鞎勲瀺鞐愲毽姼(UAE) 氤搓贝鞓堧癌攵�鞚� 鞀轨澑鞚� 氚涭晿鞀惦媹雼�. 鞚� 10攵勱皠鞚� 歆勲嫧瓴�靷姅 Helicobacter pylori(H. pylori)鞐� 雽�頃� 頃泊毳� 瓴�於滍晿氅�, 鞚� 靹戈窢鞚� UAE 鞚戈惮鞚� 41%鞐� 鞓來枼鞚� 氙胳箻瓿� 鞙勳晹 靷鞚� 鞎� 80%鞕� 甏�霠澊 鞛堨姷雼堧嫟.
鞚� 韰岇姢韸鸽姅 UAE鞐� 旮半皹鞚� 霊� 韺岉姼雱堧ゼ 韱淀暣 鞙犿喌霅橂┌ 鞎疥淡, 韥措Μ雼� 氚� 鞓澕鞚� 頂岆灚韽检棎靹� 鞝滉车霅� 鞓堨爼鞛呺媹雼�. H. pylori電� WHO臧� 1甑� 氚滌晹氍检搿� 攵勲頄堨溂氅�, 旃橂頃橃 鞎婌溂氅� 臧愳椉鞛愳潣 斓滊寑 20%鞐愳劀 鞙勱钉鞏� 氚� 鞙勳晹鞚� 韽暔頃� 鞁皝頃� 頃╇硲歃濎潉 齑堧灅頃� 靾� 鞛堨姷雼堧嫟. 鞚措矆 鞀轨澑鞚� EZ Detect鈩� Colon Disease Test鞚� 靹标车鞝侅澑 於滌嫓鞐� 鞚挫柎 Biomerica鞚� 欷戨彊 鞁滌灔 雮� 鞛呾毳� 臧曧檾頃╇媹雼�.
Biomerica (Nasdaq: BMRA) a obtenu l'autorisation du Minist猫re de la Sant茅 et de la Pr茅vention des EAU pour son Fortel庐 Ulcer Test 脿 usage domestique. Ce test diagnostique de 10 minutes d茅tecte les anticorps dirig茅s contre Helicobacter pylori (H. pylori), une bact茅rie qui touche 41% de la population des EAU et est li茅e 脿 environ 80% des cas de cancer gastrique.
Le test sera distribu茅 via des partenaires bas茅s aux EAU et disponible en pharmacies, cliniques et sur les plateformes en ligne. H. pylori, class茅e par l'OMS comme canc茅rog猫ne de classe 1, peut entra卯ner des complications graves chez jusqu'脿 20% des personnes infect茅es si elle n'est pas trait茅e, notamment des ulc猫res peptiques et un cancer gastrique. Cette autorisation renforce la pr茅sence de Biomerica sur le march茅 du Moyen-Orient, apr猫s le lancement r茅ussi du EZ Detect鈩� Colon Disease Test.
Biomerica (Nasdaq: BMRA) hat die Zulassung des Fortel庐 Ulcer Test zur Anwendung zu Hause durch das Ministerium f眉r Gesundheit und Pr盲vention der VAE erhalten. Dieser 10-min眉tige Schnelltest erkennt Antik枚rper gegen Helicobacter pylori (H. pylori), ein Bakterium, das 41% der Bev枚lkerung der VAE betrifft und mit etwa 80% der Magenkrebsf盲lle in Verbindung gebracht wird.
Der Test wird 眉ber in den VAE ans盲ssige Partner vertrieben und in Apotheken, Kliniken sowie 眉ber Online-Plattformen erh盲ltlich sein. H. pylori, von der WHO als Karzinogen der Gruppe 1 eingestuft, kann unbehandelt bei bis zu 20% der Infizierten zu schweren Komplikationen f眉hren, darunter peptische Geschw眉re und Magenkrebs. Diese Zulassung st盲rkt Biomericas Pr盲senz im Markt des Nahen Ostens nach dem erfolgreichen Start des EZ Detect鈩� Colon Disease Test.
- Regulatory approval in UAE expands market access for Fortel庐 Ulcer Test
- Large target market with 41% of UAE population affected by H. pylori
- Strategic partnerships with UAE distributors for widespread distribution
- Strengthens company's Middle East presence following previous successful product launches
- Faces competition in a market with existing H. pylori testing solutions
- Success dependent on consumer adoption of home testing concept
Insights
Biomerica's UAE approval for home H. pylori testing opens significant market opportunity in region with 41% infection prevalence.
The UAE Ministry of Health and Prevention's approval of Biomerica's Fortel庐 Ulcer Test represents a strategic market expansion for the company's diagnostic portfolio. This rapid test targets H. pylori, which affects approximately
The clinical significance here is substantial. H. pylori is classified as a Class 1 carcinogen by the WHO and is linked to roughly
What makes this approval particularly valuable is the home-use designation, which removes healthcare setting constraints and dramatically expands accessibility. The 10-minute test format addresses the critical need for convenient screening in a region where up to
This approval complements Biomerica's existing Middle East presence, following their EZ Detect鈩� Colon Disease Test. The distribution partnerships mentioned will be crucial for market penetration across pharmacies, clinics, and online platforms. For a diagnostic company, securing regulatory approvals that expand addressable markets is a fundamental growth driver, especially when targeting conditions with high prevalence rates.
- 10-minute home test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancer
- H. pylori linked to approximately
80% of gastric cancer cases; classified as a Class 1 carcinogen by the World Health Organization - Gastric cancer ranks as the fifth most common cancer globally and the fourth leading cause of cancer-related deaths
IRVINE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, today announced that the United Arab Emirates (UAE) Ministry of Health and Prevention has approved Biomerica鈥檚 Fortel庐 Ulcer Test for home use. This marks a milestone in expanding access to accurate, easy-to-use diagnostic tools for one of the leading causes of gastric disease in the region.
The Fortel庐 Ulcer Test is a 10-minute rapid diagnostic test that detects antibodies to Helicobacter pylori (H. pylori), a bacterium responsible for peptic ulcers, dyspepsia, and a significant portion of gastric cancer cases. With this new regulatory approval, individuals across the UAE can now self-administer the test in the comfort and privacy of their own homes.
A Widespread and Dangerous Infection
H. pylori affects approximately
Expanded Access and Regional Impact
With home-use approval now in place, Biomerica is partnering with UAE-based distributors and healthcare providers to make the Fortel庐 Ulcer Test available at pharmacies, clinics, and online platforms. This approval strengthens Biomerica鈥檚 growing presence in the Middle East, building on the successful regional launch of the EZ Detect鈩� Colon Disease Test and other diagnostics designed for early detection and better patient outcomes.
鈥淲ith this home-use approval, we鈥檙e giving people direct access to a reliable tool for early detection of a dangerous infection that could result in serious complications,鈥� said Zack Irani, CEO of Biomerica. 鈥淭his can help drive earlier and more effective medical treatment and potentially save lives.鈥�
Committed to Early Detection and Better Health Outcomes
Biomerica remains focused on delivering affordable, innovative diagnostic tools that improve patient outcomes through early disease detection. The Fortel庐 Ulcer Test exemplifies an easy to implement solution in the fight against H. pylori-related illnesses and reflects the Company鈥檚 mission to improve global health with accessible and effective diagnostics.
About Biomerica (NASDAQ: )
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the Company鈥檚 current and future sales, revenues, overhead, expenses, cost of goods, operations and earnings, efficacy of the Company鈥檚 products and tests including the Fortel庐 Ulcer Test, FDA and/or international regulatory authorization for the Company鈥檚 products to be marketed and sold, including the Fortel庐 Ulcer Test, and the Company鈥檚 other current and future products, the possible expansion in to other markets, uniqueness of the Company鈥檚 products, accuracy of the Company鈥檚 tests and products, pricing of the Company鈥檚 test kits, domestic and/or international market adoption and acceptance and demand for the Company鈥檚 products including the Fortel庐 Ulcer Test, future use of the Company's products by physicians to treat their patients, potential revenues from the sale of current or future products. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results, in the future, including, without limitation: earnings and other financial results; results of studies testing the efficacy of the Company鈥檚 inFoods tests and other products; regulatory approvals necessary prior to commercialization of the Company鈥檚 products; availability of the Company鈥檚 test kits and other products; capacity, shipping logistics, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; regulatory compliance and oversite, and the Company鈥檚 ability to obtain patent protection on any aspects of its diagnostic or therapeutic technologies. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.
Corporate Contact:
Zack Irani聽|聽CEO
p. 949.645.2111
Source: Biomerica
FAQ
What is the significance of Biomerica's (BMRA) Fortel庐 Ulcer Test approval in UAE?
How prevalent is H. pylori infection in the UAE market for BMRA's test?
What are the potential complications of H. pylori that BMRA's test can help detect?
How will Biomerica distribute the Fortel庐 Ulcer Test in the UAE?
What is the WHO classification of H. pylori that BMRA's test detects?
